SAR341402 vs THDB0206
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor · full Type 2 Diabetes pipeline
SAR341402
Marketed by Sanofi
NCT03211858 · Phase 3 · completed
The trial randomized 597 participants to SAR341402 or active-control NovoLog/NovoRapid, but treatment assignment was not blinded. The primary HbA1c endpoint met the prespecified non-inferiority margins, while HbA1c is a surrogate measure, so the evidence is considered moderate rather than strong.
Reported efficacy
Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26 (Baseline, Week 26): Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26 (Baseline, Week 26): SAR341402 -0.38 percentage of HbA1c (Standard Error 0.042) vs NovoLog/NovoRapid -0.3 percentage of HbA1c (Standard Error 0.041) (met)
Result source: NCT03211858
THDB0206
Developed by Adocia and partners
NCT05834868 · Phase 3 · completed
The study was randomized and actively controlled with insulin lispro, but it was open-label and used change in HbA1c as its primary, surrogate endpoint rather than a hard clinical outcome. Registry results are not posted; the sponsors (Adocia and Tonghua Dongbao) announced positive topline results versus Humalog in July 2025, so the result rests on a company announcement.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
No aligned efficacy figure on record for this race.
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | SAR341402 | THDB0206 |
|---|---|---|
| HbA1c, change | -0.4% vs -0.3%vs NovoLog/NovoRapidNCT032118581 other result
| —Not posted · NCT05834868 |
| Body weight, change (kg) | —Not reported | —Not posted · NCT05834868 |
| HbA1c below 7% | 19.6% vs 18.2%vs NovoLog/NovoRapidNCT032118581 other result
| —Not posted · NCT05834868 |
| Fasting plasma glucose, change | -0.1 vs -0.3vs NovoLog/NovoRapidNCT032118581 other result
| —Not posted · NCT05834868 |
| 3-point MACE (% with event) | —Not reported | —Not posted · NCT05834868 |
HbA1c, change
- SAR341402
- -0.4% vs -0.3%vs NovoLog/NovoRapidNCT03211858
1 other result
- -0.3% vs -0.3% NCT03211858
- THDB0206
- —Not posted · NCT05834868
Body weight, change (kg)
- SAR341402
- —Not reported
- THDB0206
- —Not posted · NCT05834868
HbA1c below 7%
- SAR341402
- 19.6% vs 18.2%vs NovoLog/NovoRapidNCT03211858
1 other result
- 16.6% vs 14.5% NCT03211858
- THDB0206
- —Not posted · NCT05834868
Fasting plasma glucose, change
- SAR341402
- -0.1 vs -0.3vs NovoLog/NovoRapidNCT03211858
1 other result
- -0.5 vs -0.2 NCT03211858
- THDB0206
- —Not posted · NCT05834868
3-point MACE (% with event)
- SAR341402
- —Not reported
- THDB0206
- —Not posted · NCT05834868
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
THDB0206: no structured comparison results are available for Type 2 Diabetes.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. SAR341402: 4 of 4 rows · THDB0206: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | SAR341402 |
|---|---|
| Dropout rate | 12.3% NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3 |
| Discontinued due to AEs | 2.7% NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3 |
| Serious AEs | 12% NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3 |
| Most frequent reported AEs | nasopharyngitis 11.3% upper respiratory tract infection 7.3% influenza 5% NCT03211858 · Phase 3 · combination · Type 1 Diabetes, Type 2 Diabetes · phase 3 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
SAR341402
show 1 more result
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: SAR341402's landscape · THDB0206's landscape